Patient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study

Abstract

BackgroundThe Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient‐Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD measures the impact of dermatological conditions on the patient's life.ObjectivesThis study aimed to seek consensus from patients on which items to prioritize for inclusion in PRIDD.MethodsA modified, two‐round Delphi study was conducted. Adults (≥18 years) with dermatological conditions were recruited. The survey consisted of a demographic's questionnaire and 263 potential impact items in six languages. Quantitative data used Likert‐type ranking scales and analysed against consensus criteria. Qualitative data collected free text responses for additional feedback and a framework analysis was conducted.Results1154 people representing 90 dermatological conditions from 66 countries participated. Items were either removed (n = 79), edited (n = 179) or added (n = 2), based on consensus thresholds and qualitative feedback. Results generated the first draft of PRIDD with 27 items across five impact domains.ConclusionThis Delphi study resulted in the draft version of PRIDD, ready for psychometric testing. The triangulated data helped refine the existing conceptual framework of impact. PRIDD has since been pilot tested with patients and is currently undergoing psychometric testing.